Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.

Vranic, Semir; Basu, Gargi D; Hall, David W; Gatalica, Zoran

Vranic, Semir; Basu, Gargi D; Hall, David W; Gatalica, Zoran.

Afiliación

Vranic S; College of Medicine, QU Health, Qatar University, Doha, Qatar; Department of Medical Sciences, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina. semir.vranic@gmail.com; svranic@qu.edu.qa.
Basu GD; Exact Sciences, Phoenix, Arizona, United States of America.
Hall DW; Exact Sciences, Phoenix, Arizona, United States of America.
Gatalica Z; Exact Sciences, Phoenix, Arizona, United States of America; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.

Acta Med Acad ; 51(3): 217-231, 2022 Dec.

Article en En | MEDLINE | ID: mdl-36799315

Asunto(s)

Neoplasias Encefálicas; Proteínas Proto-Oncogénicas B-raf; Humanos; Proteínas Proto-Oncogénicas B-raf/genética; Mutación; Medicina de Precisión

Palabras clave

BRAF; BRAF Inhibitors; Molecular Diagnostics; Precision Medicine; Targeted Therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Proteínas Proto-Oncogénicas B-raf Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Acta Med Acad Año: 2022 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google